HK Stock Market Move | GENSCRIPT BIO (01548) Surges Over 8% Again, Total Market Cap Tops HK$100 Billion, Recently Partnered with Lilly TuneLab

GENSCRIPT BIO (01548) rose over 8% again, with cumulative gains nearing 270% since early July. As of press time, it was up 8.16% at HK$44.78, with a turnover of HK$438 million and total market capitalization surpassing HK$100 billion. On the news front, on September 16, the company announced a partnership with Lilly's AIDD collaboration platform, Lilly TuneLab. Under the agreement, the company will provide wet lab services to TuneLab-participating enterprises, helping them rapidly generate experimental data, convert AI predictions into biological validation data, and accelerate candidate drug evaluation. JPMorgan stated that Lilly TuneLab's selection of GenScript as one of three core wet lab partners signifies more than just a single CRO order, but rather a strategic entry point into an ecosystem of over 100 biotech clients and a closed loop integrating dry and wet lab processes. Shanxi recently released a research report stating that TWIST is the leading company in this round of AI pharmaceutical stock gains, serving as a core industry target for undertaking AIDD orders from companies such as Anthropic, with its stock price continuously hitting new highs. Year-to-date, its stock price has risen 476%, with a single-day gain of over 16% on September 25, continuously fueling sector enthusiasm. AI pharmaceuticals have become the strongest mainline in the current pharmaceutical sector. MNCs are actively positioning themselves in AI pharmaceuticals. In September, Novo Nordisk announced integration with the Claude large model, Lilly's Lilly TuneLab successively signed agreements with GenScript, Twist, and Ginkgo Bioworks, and AbbVie reached a collaboration agreement with Lambic.